- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior
A panel of experts discusses the ways in which payers restrict prescribing choices for physicians and what that means for the future of biosimilar utilization.
On July 20, 2020, MJH Life Sciences™ hosted the webinar "How Biosimilar Rebates Shape Payer Policies, Provider Behavior." Jeff Prescott, PharmD, senior vice president of Clinical Communications for MJH Life Sciences™ served as moderator. The panelists were Kathy Oubre, MS, chief operating officer of the Pontchartrain Cancer Center in Louisiana; Timothy Chiu, PharmD, BCPS, pharmacist evidence analyst and strategist for Kaiser Permanente; and Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator of Hematology/Oncology for The University of Arizona Cancer Center in Tucson.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
